Umbilical cord mesenchymal stem cells and breast cancer: a good therapeutic candidate or not? A minireview.
Breast cancer
Mesenchymal stem cells
Pathogenesis
Umbilical cord
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
18
03
2022
accepted:
22
06
2022
revised:
09
06
2022
pubmed:
9
8
2022
medline:
14
9
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Breast cancer (BC), as the most common cancer among women, affects a great number of subjects around the world. This heterogenic disease is divided into several types and subtypes, and each subtype has various phenotypes and genotypes. Against BC, several options have been proposed, such as surgery, radiotherapy, and chemotherapeutic agents. However, these approaches may have detrimental effects on health and life quality of patients. Hence, harnessing a therapeutic tool with high effectiveness and low side effects is required. Recently, mesenchymal stem cells (MSCs) have created a new window to treat various disorders, like cancer, and among these, umbilical cord (UC)-derived MSCs have acquired much interest due to their advantages. Therefore, in this narrative review, the influences of UC-derived MSCs on BC were reviewed and summarized with a focus on the molecular mechanisms involved in its pathogenesis and treatment.
Identifiants
pubmed: 35941415
doi: 10.1007/s11033-022-07739-w
pii: 10.1007/s11033-022-07739-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9017-9022Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy 11:151
Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K et al (2021) Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med 18(3):900–909
pmcid: 8330522
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK (2010) Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 1(2):109–126
pubmed: 22247839
pmcid: 3255438
Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564
pubmed: 21436443
Wu J, Hicks C (2021) Breast Cancer Type Classification Using Machine Learning.J Pers Med. ; 11(2)
Wang L, Zhang S, Wang X (2021) The metabolic mechanisms of breast cancer metastasis. Front Oncol 10:2942
Barros-Oliveira MdC, Costa-Silva DR, Dos Santos AR, Pereira RO, Soares-Júnior JM (2021) Silva BBd. Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature.Clinics. ; 76
Ammembal AMK, Udupa K (2021) Combined Oral Contraceptives and Breast Cancer: an Unsolved Conundrum. Indian J Gynecologic Oncol 19(4):67
Wang Y, Zhou X, Wang W, Wu Y, Qian Z, Peng Q (2021) Sodium bicarbonate, an inorganic salt and a potential active agent for cancer therapy.Chinese Chemical Letters.
Hussain Y, Islam L, Khan H, Filosa R, Aschner M, Javed S (2021) Curcumin–cisplatin chemotherapy: A novel strategy in promoting chemotherapy efficacy and reducing side effects.Phytotherapy Research.
Luan S, Zeng X, Zhang C, Qiu J, Yang Y, Mao C et al (2021) Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment.Frontiers in Cell and Developmental Biology. ; 9(623)
Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V (2020) Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol 8:43
pubmed: 32117924
pmcid: 7013101
ArefNezhad R, Motedayyen H, Mohammadi A (2021) Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review. Int J Stem Cells 14(3):241–251
pubmed: 34158417
pmcid: 8429946
Rao VV, Vu MK, Ma H, Killaars AR, Anseth KS (2019) Rescuing mesenchymal stem cell regenerative properties on hydrogel substrates post serial expansion. Bioeng Translational Med 4(1):51–60
Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B (2006) Aging of mesenchymal stem cell in vitro. BMC Cell Biol 7(1):14
pubmed: 16529651
pmcid: 1435883
Markarian CF, Frey GZ, Silveira MD, Chem EM, Milani AR, Ely PB et al (2014) Isolation of adipose-derived stem cells: a comparison among different methods. Biotechnol Lett 36(4):693–702
pubmed: 24322777
Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K (2004) Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22(5):649–658
pubmed: 15342929
Schwab KE, Hutchinson P, Gargett CE (2008) Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. Hum Reprod 23(4):934–943
pubmed: 18305000
Ma F, Chen D, Chen F, Chi Y, Han Z, Feng X et al (2015) Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8-and interleukin-6-dependent induction of CD44+/CD24-cells. Cell Transplant 24(12):2585–2599
pubmed: 25695620
Rahmani F, Ferns GA, Talebian S, Nourbakhsh M, Avan A, Shahidsales S (2020) Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer. Gene 737:144459
pubmed: 32045660
King J, Mir H, Singh S (2017) Chapter Four - Association of Cytokines and Chemokines in Pathogenesis of Breast Cancer. In: Lakshmanaswamy R (ed) Progress in Molecular Biology and Translational Science, vol 151. Academic Press, pp 113–136
Hulka BS, Liu ET, Lininger RA (1994) Steroid hormones and risk of breast cancer. Cancer 74(S3):1111–1124
pubmed: 8039146
Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10):1721–1730
pubmed: 28085182
Nazari E, ArefNezhad R, Tabadkani M, Farzin AH, Tara M, Hassanian SM et al (2021) Using correlation matrix for the investigation the interaction of genes and traditional risk factor in breast cancer. Meta Gene 30:100947
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L et al (2018) Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & Diseases 5(2):77–106
Renoir J-M, Marsaud V, Lazennec G (2013) Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 85(4):449–465
pubmed: 23103568
Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer metastasis. International journal of breast cancer. ;2012
Said TK, Conneely OM, Medina D, O’Malley BW, Lydon JP (1997) Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 138(9):3933–3939
pubmed: 9275084
Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R et al (2004) Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 24(16):7260–7274
pubmed: 15282324
pmcid: 479712
Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88(3):405–415
pubmed: 9039267
Lundberg A, Weinberg R (1999) Control of the cell cycle and apoptosis1. Eur J Cancer 35(14):1886–1894
pubmed: 10711231
King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erb B-related gene in a human mammary carcinoma. Science 229(4717):974–976
pubmed: 2992089
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
pubmed: 3798106
Brennan KR, Brown A (2004) Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 9(2):119–131
pubmed: 15300008
Bafico A, Liu G, Goldin L, Harris V, Aaronson SA (2004) An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6(5):497–506
pubmed: 15542433
King TD, Suto MJ, Li Y (2012) The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 113(1):13–18
pubmed: 21898546
Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17(1):45–51
pubmed: 17208432
MacDonald BT, Tamai K, He X (2009) Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases. Dev Cell 17(1):9–26
pubmed: 19619488
pmcid: 2861485
Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9(9):665–674
pubmed: 19693095
Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A (2005) The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 217(1):73–86
pubmed: 15596298
Filippi I, Carraro F, Naldini A (2015) Interleukin-1β affects MDAMB231 breast cancer cell migration under hypoxia: role of HIF-1α and NFκB transcription factors.Mediators of Inflammation. ; 2015
Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, Carraro F (2010) Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α. Eur J Cancer 46(18):3400–3408
pubmed: 20801015
Bhattacharjee HK, Bansal VK, Nepal B, Srivastava S, Dinda AK, Misra MC (2016) Is interleukin 10 (IL10) expression in breast cancer a marker of poor prognosis? Indian J Surg Oncol 7(3):320–325
pubmed: 27651693
pmcid: 5016330
Zhao S, Wu D, Wu P, Wang Z, Huang J (2015) Serum IL-10 predicts worse outcome in cancer patients: A meta-analysis. PLoS ONE 10(10):e0139598
pubmed: 26440936
pmcid: 4595202
Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS (2013) Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 43(6):1518–1528
pubmed: 23529839
Wege AK, Weber F, Kroemer A, Ortmann O, Nimmerjahn F, Brockhoff G (2017) IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget 8(2):2731
pubmed: 27835865
Trabert B, Sherman ME, Kannan N, Stanczyk FZ (2020) Progesterone and Breast Cancer. Endocr Rev 41(2):320–344
Hankinson SE, Eliassen AH (2007) Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 106(1–5):24–30
pubmed: 17719770
pmcid: 2715949
Tian J, Ran B, Zhang C, Yan D, Li X (2018) Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression.Brazilian Journal of Medical and Biological Research. ; 51
Shah NR, Chen H (2014) MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment. World J Clin Oncol 5(2):48–60
pubmed: 24829851
pmcid: 4014796
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12(3):247–256
pubmed: 20173740
pmcid: 2845545
Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu F et al (2015) Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. Oncol Rep 34(3):1469–1477
pubmed: 26151310
Chao KC, Yang HT, Chen MW (2012) Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell–cell contact and internalization. J Cell Mol Med 16(8):1803–1815
pubmed: 21973190
pmcid: 3822693
Ohta N, Ishiguro S, Kawabata A, Uppalapati D, Pyle M, Troyer D et al (2015) Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS ONE 10(5):e0123756
pubmed: 25942583
pmcid: 4420498
Ma Y, Hao X, Zhang S, Zhang J (2012) The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Res Treat 133(2):473–485
pubmed: 21947651
Mirabdollahi M, Haghjooyjavanmard S, Sadeghi-Aliabadi H (2019) An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line. Cell Tissue Banking 20(3):423–434
pubmed: 31338647
Zhou X, Li T, Chen Y, Zhang N, Wang P, Liang Y et al (2019) Mesenchymal stem cell–derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway. Int J Oncol 54(5):1843–1852
pubmed: 30864702
Khazaei-Poul Y, Shojaei S, Koochaki A, Ghanbarian H, Mohammadi-Yeganeh S (2021) Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells. Life Sci 286:120015
pubmed: 34614416
Di G-h, Liu Y, Lu Y, Liu J, Wu C, Duan H-F (2014) IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS ONE 9(11):e113572
pubmed: 25419563
pmcid: 4242635
Liu X, Hu J, Sun S, Li F, Cao W, Wang Y et al (2015) Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro. Exp Ther Med 9(4):1192–1200
pubmed: 25780408
pmcid: 4353741
Shen C-J, Chan T-F, Chen C-C, Hsu Y-C, Long C-Y, Lai C-S (2016) Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis. Oncotarget 7(23):34172–34179
pubmed: 27129156
pmcid: 5085146
Du L, Tao X, Shen X (2021) Human umbilical cord mesenchymal stem cell-derived exosomes inhibit migration and invasion of breast cancer cells via miR-21-5p/ZNF367 pathway. Breast Cancer 28(4):829–837
pubmed: 33770377
Cao S, Guo J, He Y, Alahdal M, Tang S, Zhao Y et al (2018) Nano-loaded human umbilical cord mesenchymal stem cells as targeted carriers of doxorubicin for breast cancer therapy. Artif Cells Nanomed Biotechnol 46(sup1):642–652
pubmed: 29457930